Efgartigimod in Myasthenia Gravis: Peak Benefit Real, Durability and MuSK Data Thin
This tiered meta-analysis separates randomized from uncontrolled efgartigimod evidence in generalized myasthenia gravis and quantifies how much confidence each tier supports, including the loss of benefit by end of follow-up.
📅 Journal publication: Nov 2026·Last updated: Nov 15, 2026
Efgartigimod shows promise for short-term gMG symptom relief.
Generalized myasthenia gravis (gMG) significantly impacts quality of life and current treatments have limitations. Efgartigimod improved MG-ADL and QMG scores in RCTs with an adverse event rate similar to placebo. While RCTs showed short-term efficacy, real-world data were heterogeneous and indicate a need for cyclical retreatment. Efgartigimod improves gMG symptoms short-term, but long-term benefit needs further study.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Ahmed GU, Ramsha F, Kinger S, Shaikh JG, Prejna F, Ritik F, Shabir I, Suhail F, Basit MA, Moiz M, Ali A, Manan A, Samadi A, Raza AA
Citation:Ahmed GU, Ramsha F, Kinger S, et al. Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis. Brain and behavior. 2026;16(11). doi:10.1002/brb3.71875